Collegium Pharmaceutical (NASDAQ:COLL) Rating Reiterated by Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Collegium Pharmaceutical (NASDAQ:COLL) in a research report sent to investors on Friday, Benzinga reports.

Several other brokerages have also issued reports on COLL. HC Wainwright upgraded shares of Collegium Pharmaceutical from a neutral rating to a buy rating and set a $47.00 target price for the company in a research report on Tuesday, July 30th. Jefferies Financial Group upgraded Collegium Pharmaceutical from a hold rating to a buy rating and upped their price objective for the stock from $41.00 to $44.00 in a report on Friday, June 7th. Piper Sandler cut Collegium Pharmaceutical from an overweight rating to a neutral rating and set a $39.00 price objective on the stock. in a report on Friday, May 10th. Finally, StockNews.com downgraded Collegium Pharmaceutical from a strong-buy rating to a buy rating in a research report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Collegium Pharmaceutical has an average rating of Moderate Buy and an average target price of $42.00.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $35.62 on Friday. Collegium Pharmaceutical has a twelve month low of $20.95 and a twelve month high of $40.95. The company has a quick ratio of 1.14, a current ratio of 1.21 and a debt-to-equity ratio of 1.98. The stock has a market cap of $1.17 billion, a P/E ratio of 14.84 and a beta of 0.93. The business’s 50-day moving average price is $33.16 and its two-hundred day moving average price is $34.86.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. The business had revenue of $145.28 million for the quarter, compared to the consensus estimate of $143.94 million. During the same period last year, the firm posted $1.13 earnings per share. Collegium Pharmaceutical’s quarterly revenue was up 7.2% on a year-over-year basis. As a group, equities analysts predict that Collegium Pharmaceutical will post 5.73 EPS for the current fiscal year.

Insider Activity

In related news, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. In other Collegium Pharmaceutical news, EVP Scott Dreyer sold 56,807 shares of the stock in a transaction on Friday, May 24th. The shares were sold at an average price of $33.98, for a total transaction of $1,930,301.86. Following the completion of the sale, the executive vice president now owns 105,902 shares of the company’s stock, valued at approximately $3,598,549.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Colleen Tupper sold 19,710 shares of the firm’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total transaction of $674,279.10. Following the completion of the sale, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by corporate insiders.

Institutional Trading of Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the company. Inspire Investing LLC increased its holdings in Collegium Pharmaceutical by 13.3% during the 2nd quarter. Inspire Investing LLC now owns 24,798 shares of the specialty pharmaceutical company’s stock valued at $798,000 after purchasing an additional 2,917 shares during the period. Renaissance Technologies LLC grew its position in shares of Collegium Pharmaceutical by 8.0% in the 2nd quarter. Renaissance Technologies LLC now owns 1,531,498 shares of the specialty pharmaceutical company’s stock worth $49,314,000 after buying an additional 113,300 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Collegium Pharmaceutical by 2.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,039,024 shares of the specialty pharmaceutical company’s stock valued at $33,457,000 after buying an additional 19,876 shares during the period. BOKF NA bought a new position in shares of Collegium Pharmaceutical during the second quarter valued at approximately $490,000. Finally, American Century Companies Inc. lifted its stake in Collegium Pharmaceutical by 8.8% in the second quarter. American Century Companies Inc. now owns 99,808 shares of the specialty pharmaceutical company’s stock worth $3,214,000 after acquiring an additional 8,097 shares during the period.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.